Expanding health data analysis capacity
Oslo Economics appears to be strengthening its capability to work with health‑related register data, drug utilisation and assessment of new medicines. The firm is highlighting a range of projects that involve detailed cost, activity and productivity analyses for health authorities and pharmaceutical clients.
Public signs include presentations at a European health‑economics conference, multiple reports for national decision‑making bodies, and a series of formal requests and agreements to access and process national patient registers and other health data sources.
-
Oslo Economics announced that several colleagues will attend ISPOR Europe 2026 to present recent work in health economics, including drug‑related analyses.
-
Dagens Medisin reported an Oslo Economics report for LMI on how DMP and the Decision Forum value new medicines, indicating a focus on drug‑economics and decision processes.
-
The Oslo Economics report on the value of new medicines describes manual extraction of variables from methodological assessments, including budget impact, drug costs, patient numbers, health gains and severity.
-
Oslo Economics highlighted multiple health‑ and drug‑related assignments on its homepage, such as cost, activity and productivity analysis for the Ministry of Health and a knowledge base on cardiac rehabilitation for Amgen and Novartis.
-
Oslo Economics received a decision granting a dispensation from confidentiality and access to health information in case H‑3162 related to the use of PCSK9 inhibitors in Norway.
-
eInnsyn shows a signed agreement with DMP for processing drug data, supporting a more operational health‑data and drug‑data capacity.